Mehul Gandhi joins Exobiosphere as Chief Financial Officer

Exobiosphere, the space biotechnology company advancing drug discovery and biomedical research in microgravity, has appointed Mehul Gandhi as Chief Financial Officer. Mehul joins as the company kicks prepares for a series of orbital missions beginning in 2027, when its platform is contracted for permanent installation aboard the International Space Station and VAST's Haven-1 Commercial Space Station. He will lead capital strategy, pricing, and financial infrastructure as Exobiosphere scales from mission services into long-term pharmaceutical partnerships. 

Mehul brings more than 15 years of capital markets and deep-tech operating experience to the role. He spent eleven years at Morgan Stanley's Investment Banking Division in New York, most recently as Executive Director in the Global Industrials Group, where he advised on more than 60 transactions representing over $125 billion in cumulative value and led execution on 15+ capital raises. Over that time, he helped raise more than $2 billion in private capital from venture, sovereign, strategic and institutional investors, and supported more than $15 billion in public capital markets execution for clients. His M&A work included marquee industrial transactions — GE Oil & Gas's $33 billion merger with Baker Hughes and GE Transportation's $11 billion merger with Wabtec. 

He then served as Chief Financial Officer of OffWorld, the space robotics company, where he oversaw fundraising, investor relations, corporate development, FP&A, accounting, and tax. He also served as a Partner at Space Gate Capital, an emerging private equity fund focused on space and defense technology, where he lead due diligence, transaction structuring, and portfolio operations. 

Mehul holds an MBA from the Haas School of Business at the University of California, Berkeley, a master's degree in mechanical engineering from the University of Michigan, and a bachelor's degree in mechanical engineering from the Manipal Institute of Technology. 
 
"Most space companies are still looking for a market. Exobiosphere has customers, contracted missions, and revenue before its first flight, and that is not something I have seen at this stage. Microgravity is going to become a standard tool in drug development, and whoever industrializes it first defines the category. I came here to make sure we are capitalized to be that company" said Mehul Gandhi. 

"Mehul is someone I have known and worked with for years. He brings the financial acumen, operating discipline, and capital markets experience needed to build a multibillion-dollar company. I'm grateful to have him on board as we prepare for our next major financial milestones, scale the team, and expand our products across numerous platforms on Earth and in space” said Kyle Acierno, CEO of Exobiosphere. 

Mehul Gandhi